17:33 , Mar 2, 2018 |  BC Week In Review  |  Financial News

BioMedPartners closes third fund at CHF100M

BioMedPartners (Basel, Switzerland) closed its BioMedInvest III fund at CHF100 million ($107 million). The firm plans to invest the fund in 12-15 private early to mid-stage pharmaceutical, medical device and diagnostics companies in Switzerland, Germany...
18:11 , Mar 1, 2018 |  BC Extra  |  Financial News

BioMedPartners closes third fund

BioMedPartners closed its BioMedInvest III fund at CHF100 million ($107 million). The firm plans to invest the fund in 12-15 private early to mid-stage pharmaceutical, medical device and diagnostics companies in Switzerland, Germany and neighboring...
22:03 , Aug 31, 2017 |  BioCentury  |  Finance

Fund fine-tuning

BioMedPartners is fine-tuning its strategy for its third fund to focus more on therapeutics investments, where the firm has seen most of its biggest returns. The Swiss VC told BioCentury BioMedInvest III has reached an...
12:24 , May 26, 2017 |  BC Week In Review  |  Financial News

BioMedPartners announced first closing of BioMedInvest III at CHF75M

In February, BioMedPartners (Basel, Switzerland) announced the first closing of its BioMedInvest III fund at CHF75 million ($76.9 million). The fund expects to invest in 12-16 private early to mid-stage healthcare companies in Europe and...
08:00 , Feb 26, 2015 |  BC Innovations  |  Finance

Europe waking to the American dream

While Europe didn't see the spike in seed and series A financing that the U.S. biotech sector enjoyed in 2014, there are signs the region is beginning to capitalize on the strength of its academic...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Financial News

Anergis completes venture financing

Anergis S.A. , Epalinges, Switzerland   Business: Inflammation   Date completed: 2014-12-03   Type: Venture financing   Raised: CHF14.5 million ($14.8 million)   Investors: Sunstone Capital; BioMedInvest; Renaissance PME; WJFS  ...
08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Pollen for Anergis

By topping off its series B financing, Anergis S.A. hopes to make its short-term birch pollen allergy vaccine into a long-term winner. The additional CHF14.5 million ($15 million) in funding brings the series B total...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Financial News

Curetis financial update

Curetis AG , Holzgerlingen, Germany   Business: Diagnostic   Date announced: 2014-11-24   Note: Curetis raised €14.5 million ($18 million) in an extension of a series B financing, bringing the total raised to €27 million...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Financial News

ImevaX completes venture financing

ImevaX GmbH , Munich, Germany   Business: Infectious   Date completed: 2014-10-28   Type: Venture financing   Raised: EUR7.5 million ($9.5 million)   Investors: Wellington Partners; BioMedInvest; BioMedPartners; EMBL Ventures; Santo Venture Capital  ...
01:33 , Sep 13, 2014 |  BC Extra  |  Financial News

Affimed raises $56M in IPO

Affimed Therapeutics B.V. (NASDAQ:AFMD) was down $1.30 to $5.70 on its first day of trading Friday after raising $56 million through the sale of 8 million shares at $7 in an IPO. The IPO price...